Finally, the ongoing GLP-1 receptor agonist (GLP-1RAs) trials are predicting a new era in the treatment of chronic kidney disease (CKD) and cardiovascular disease (CVD) in type 2 diabetes (T2D). This evidence concerns the gene GLP1R and cardiovascular disorder.